?>
Contact us
Follow Us
About Us
Members
Executive Director
Why Biosimilars
The Issue
Our Solutions
Biosimilars 101
Foundations
Core Principles
FDA Regulatory Tenets
Biosimilars FAQs
Future Evolution of Biosimilar Development
Approved Biosimilars
Advocacy
Our Action
Tools
News
Resources
Get Involved
Partners
signalgroup
Get more out of your business.
Reach it with Microsoft Dynamics 365 Business Central.
News
March 31, 2022
signalgroup
HHS Inspector General Report: Biosimilars Could Generate Significant Medicare Part D Savings
News
March 9, 2022
signalgroup
Biosimilars Forum Executive Director to Discuss Current Biosimilars Landscape at World Biosimilars Congress
News
March 2, 2022
signalgroup
The Biosimilars Forum Calls on President Biden to Incentivize Biosimilars to Lower Prescription Drug Costs
News
March 1, 2022
signalgroup
Biosimilars Forum Welcomes HHS Inspector General Study on Biosimilars in Medicare Part B
News
February 22, 2022
signalgroup
Report Highlights Employer Savings from Increased Employee Access to Biosimilars
News
February 15, 2022
signalgroup
The Biosimilars Forum Congratulates Dr. Robert Califf on His Confirmation as FDA Commissioner
News
February 3, 2022
signalgroup
Biosimilars Forum Supports the Negotiated BsUFA III Agreement in Capitol Hill Testimony
News
January 31, 2022
signalgroup
Juliana M. Reed Named Executive Director of the Biosimilars Forum
News
October 21, 2021
signalgroup
Biosimilars Forum Member Spotlight: 5 Questions for Samsung Bioepis
News
October 20, 2021
signalgroup
First Biosimilar to Treat Eye Disease Gains FDA Approval
Prev page
03
04
05
06
07
Next page